[en] Asthma is a chronic inflammatory disease of the airways. Classification of asthma in different phenotypes has therapeutic implications and may lead to personalized medicine. Induced sputum is the gold standard for asthma phenotyping but is complex, time-consuming and not widely available. The combination of different biomarkers such as exhaled nitric oxide, blood eosinophils and total serum IgE levels allows the prediction of inflammatory phenotype in 58% of asthmatic patients when sputum is not available. We recently demonstrated the interest of measuring volatile organic compounds in exhaled breath to phenotype asthma. These compounds could play an important role in the future to predict the response to expensive biologicals available in severe asthma to reduce exacerbations and the use of systemic corticosteroids.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Schleich, FLorence ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Schleich FN, Asandei R, Manise M, et al. Is FeNO50 useful diagnostic tool in suspected asthma? Int J Clin Pract 2012;66:158-65.
Nekoee H, Graulich E, Schleich F, et al. Are type-2 biomarkers of any help in asthma diagnosis? ERJ Open Res 2020;6:00169-02020.
Bougard N, Nekoee H, Schleich F, et al. Assessment of diagnostic accuracy of lung function indices and FeNO for a positive methacholine challenge. Biochem Pharmacol 2020;179:113981.
Louis R, Bougard N, Guissard F, et al. Bronchodilation test with inhaled salbutamol versus bronchial methacholine challenge to make an asthma diagnosis: do they provide the same information? J Allergy Clin Immunol Pract 2020;8:618-25.e8.
Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014;108:1723-32.
Gerday S, Schleich F, Henket M, et al. Asthmatics with concordant eosinophilic disease classified according to their serum IgE status. Respir Med Res 2021;79:100797.
Maes T, Cobos FA, Schleich F, et al. Asthma inflammatory phenotypes show differential microRNA expression in sputum. J Allergy Clin Immunol 2016;137:1433-46.
da Silva J, Hilzendeger C, Moermans C, et al. Raised interferon-β, type 3 interferon and interferon-stimulated genes - evidence of innate immune activation in neutrophilic asthma. Clin Exp Allergy 2017;47:313-23.
Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest 2016;126:3279-95.
Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 2010;65:1039-44.
Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013;13:11.
Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014;44:97-108.
Demarche SF, Schleich FN, Paulus VA, et al. Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers? Respir Res 2017;18:133.
Schleich FN, Dallinga JW, Henket M, et al. Volatile organic compounds discriminate between eosinophilic and neutrophilic inflammation in vitro. J Breath Res 2016;10:016006.
Zanella D, Henket M, Schleich F, et al. Comparison of the effect of chemically and biologically induced inflammation on the volatile metabolite production of lung epithelial cells by GC×GC-TOFMS. Analyst 2020;145:5148-57.
Schleich FN, Zanella D, Stefanuto P-H, et al. Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med 2019;200:444-53.
Stefanuto P-H, Zanella D, Vercammen J, et al. Multimodal combination of GC × GC-HRTOFMS and SIFT-MS for asthma phenotyping using exhaled breath. Sci Rep 2020;10:16159.
Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102:531-8.
Demarche SF, Schleich FN, Henket MA, et al. Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre. BMJ Open 2017;7:e018186.
Demarche S, Schleich F, Henket M, et al. Step-down of inhaled corticosteroids in non-eosinophilic asthma: A prospective trial in real life. Clin Exp Allergy 2018;48:525-35.
Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:659-68.
Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9.
Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J 2019;54:1901381.
Trokart R, Demarche S, Schleich F, et al. Asthme et obésité. Rev Med Liege 2017;72:241-5.
Peerboom S, Graff S, Seidel L, et al. Predictors of a good response to inhaled corticosteroids in obesity-associated asthma. Biochem Pharmacol 2020;113994.
Dupont L, Pilette C, Schleich F, et al. Health literacy among asthma patients and treatment expectations: results of a Belgian survey. Acta Clin Belg 2020;75:141-8.
Graff S, Vanwynsberghe S, Brusselle G, et al. Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian Severe Asthma Registry. Respir Res 2020;21:214.
Schleich FN, Malinovschi A, Chevremont A, et al. Risk factors associated with frequent exacerbations in asthma. Respiratory Medicine: X 2020;2:100022.
Frix AN, Schleich F, Paulus V, et al. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. Biochem Pharmacol 2020;179:113944.
Schleich F, Graff S, Nekoee H, et al. Real-world experience with mepolizumab: Does it deliver what it has promised? Clin Exp Allergy 2020;50:687-695.
Schleich F, Vaia E-S, Pilette C, et al. Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature. J Allergy Clin Immunol Pract 2020;8:2412-2413.e2.
Graff S, Brusselle G, Hanon S, et al. Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry. J Allergy Clin Immunol Pract 2022;10:467-77.
Sun Q, Fang L, Roth M, et al. Bronchial thermoplasty decreases airway remodelling by blocking epithelium-derived heat shock protein 60 (HSP60) secretion and protein arginine methyltransferase 1 (PRMT1) in fibroblasts. Eur Respir J 2019;54:1900300.
Frix A, Heinen V, Schleich F, et al. Thermoplastie bronchique dans le traitement de l'asthme sévère. Analyse rétrospective de 10 cas traités au CHU de Liège. Rev Med Liege 2019;74:74-81.
Graff S, Demarche S, Henket M, et al. Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma. Respir Med, 2019;152:60-66.
Graff S, Bricmont N, Moermans C, et al. Clinical and biological factors associated with irreversible airway obstruction in adult asthma. Respir Med 2020;175:106202.
Calmes D, Graff S, Maes N, et al. Asthma and COPD are not risk factors for ICU stay and death in case of SARS-CoV2 infection. J Allergy Clin Immunol Pract 2021;9:160-9.
Hanon S, Brusselle G, Deschampheleire M, et al. COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry. Eur Respir J 2020;56:2002857.
Louis R, Roche N. Personalised medicine: are we ready? Eur respir Rev 2017;26:170088.
